BIOVEC LLC has a total of 21 patent applications. Its first patent ever was published in 2003. It filed its patents most often in United States, EPO (European Patent Office) and WIPO (World Intellectual Property Organization). Its main competitors in its focus markets pharmaceuticals, biotechnology and foods and drinks are GENETHOR GMBH, CRUCELL SWITZERLAND AG and BIOMUNE COMPANY.
# | Country | Total Patents | |
---|---|---|---|
#1 | United States | 9 | |
#2 | EPO (European Patent Office) | 4 | |
#3 | WIPO (World Intellectual Property Organization) | 4 | |
#4 | Canada | 2 | |
#5 | Australia | 1 | |
#6 | United Kingdom | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Biotechnology | |
#3 | Foods and drinks | |
#4 | Basic materials chemistry |
# | Technology | |
---|---|---|
#1 | Microorganisms | |
#2 | Medical preparations | |
#3 | Therapeutic chemical compounds | |
#4 | Peptides | |
#5 | Enzymes | |
#6 | Preservation of human bodies |
# | Name | Total Patents |
---|---|---|
#1 | Wong Jonathan | 19 |
#2 | Sehgal Lakshman R | 16 |
#3 | Sehgall Lakshman R | 5 |
#4 | Mousa Shaker A | 2 |
Publication | Filing date | Title |
---|---|---|
CA2674563A1 | Ex vivo and in vivo expression of the thrombomodulin gene for the treatment of cardiovascular and peripheral vascular diseases | |
US2007238685A1 | Ex vivo and in vivo expression of the thrombomodulin gene for the treatment of cardiovascular and peripheral vascular diseases | |
US2007212334A1 | Ex vivo and in vivo expression of the thrombomodulin gene for the treatment of cardiovascular and peripheral vascular diseases | |
US2007184027A1 | Ex vivo and in vivo expression of the thrombomodulin gene for the treatment of cardiovascular and peripheral vascular diseases | |
WO2006076401A2 | Composition for preserving platelets and method of using the same | |
GB0511154D0 | Ex vivo and in vivo expression of the thrombomodulin gene for the treatment of cardiovascular and peripheral vascular diseases |